Get the latest news about liver diseases and more
Physical activity plays an essential role in preventing and treating fatty liver disease by reducing liver fat accumulation and inflammation. Both aerobic and resistance exercise offer benefits for liver health. Regular exercise, including 150 to 300 minutes of moderate-intensity activity per week, can support liver health and overall well-being.
A study published in Scientific Reports investigated the relationship between periodontitis and fatty liver disease. The findings show that signs of periodontal disease, including a periodontal pocket depth greater than 6 mm and gingival bleeding, are associated with fatty liver disease and a greater degree of liver fibrosis.
Vitamin D plays an important role in fatty liver disease, including in patients with normal body weight. Recent research suggests that maintaining adequate vitamin D levels may improve liver health and metabolic parameters in affected individuals.
Elafibranor is a newly approved treatment for patients with primary biliary cholangitis (PBC) who do not respond adequately to ursodeoxycholic acid. Clinical studies show improved liver function and establish it as a promising therapeutic option.
A study published in The New England Journal of Medicine shows that Bepirovirsen significantly increases the likelihood of achieving a functional cure for chronic hepatitis B.
Fatty liver and hepatitis B can coexist and worsen liver damage. Combined treatment helps reduce inflammation, fibrosis, and disease progression.
A study suggests GST-HG141 may become an effective new hepatitis B treatment for patients with incomplete response to current antiviral therapies.
Metabolic syndrome increases the risk of bile duct cancer, especially in patients with fatty liver, where liver disease tends to be more aggressive.
20 de February de 2019
20 de October de 2021
4 de June de 2023
Hepatitis is an inflammation of the liver, and in the case of hepatitis C, caused by infection with hepatitis C virus (HCV)
Hepatitis A is an acute inflammatory disease of the liver, caused by infection with hepatitis A virus (VAH).
It is the second cause of liver transplantation in the USA and in the next 10 years is expected to be the first cause. It is a serious illness if it is not treated properly.
Up to 30% of patients with cryptogenic hepatitis can be caused by the seronegative hidden infection by hepatitis C virus (HIC).
It is a chronic progressive liver disease that mainly affects women (90% of cases) from the fourth decade of life.
It is a liver disease of an inflammatory nature and can develop chronically.